Abstract
Purpose :
To describe severe acute posterior multifocal placoid pigment epitheliopathy (APMPPE)-like uveitis in the context of ipilumumab and nivolumab therapy and to determine whether immune checkpoint inhibitor therapy may be restarted after resolution of symptoms.
Methods :
Retrospective observational case report
Results :
A patient on ipilimumab and nivolumab for metastatic melanoma developed severe acute posterior multifocal placoid pigment epitheliopathy (APMPPE)-like chorioretinopathy in both eyes. The patient was started on topical and systemic corticosteroid therapy and immune checkpoint inhibitor therapy was paused. Following resolution of ocular inflammation, patient was restarted on immune checkpoint inhibitor therapy without return of ocular symptoms (Figure 1, 2).
Conclusions :
An APMPPE-like chorioretinopathy may occur in patients undergoing immune checkpoint inhibitor (ICPI) therapy. Some patients with ICPI-related uveitis may successfully resume ICPI therapy under close collaboration with the treating oncologist.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.